<DOC>
	<DOCNO>NCT02468739</DOCNO>
	<brief_summary>Monosialotetrahexosyl ganglioside ( GM1 ) protect breast cancer patient taxanes-related neurotoxicity .</brief_summary>
	<brief_title>Effect GM1 Prevention Taxanes Induced Neurotoxicity Operable Breast Cancer</brief_title>
	<detailed_description>Taxanes key agent treatment breast cancer . However , peripheral neuropathy markedly limit use taxanes . There way relieve eliminate taxanes-related neurotoxicity . Monosialotetrahexosyl ganglioside ( GM1 ) present role neuroprotective property . This multi-center , randomize , placebo-controlled trial perform assess efficacy GM1 prevent taxanes induce neurotoxicity operable breast cancer patient receive taxanes-based adjuvant chemotherapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Age : 1865 year old , female Histologically confirm diagnosis invasive adenocarcinoma Intends receive least 4 cycle taxanesbased adjuvant chemotherapy prior level peripheral nerve system disease With capability accurately record occurrence severity neurotoxicity questionnaire With normal function major organ No contraindication chemotherapy Patients provide sign Informed Consent Form Patients expect able complete adjuvant chemotherapy Be allergic GM1 Hereditary abnormal metabolism glucose lipid Doctors believe patient suitable receive GM1 treatment With confirmed history neurological psychiatric disorder , include epilepsy dementia With concomitant disease seriously harm patient ' safety impact completion study Patients fertility possibility willing take effective contraceptive measure</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>